Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a contrast media presented as a 0.5 ml/0.5 mmol injection for intravenous use. It enhances magnetic resonance imaging (MRI) scans, helping radiologists visualize vascular structures and tissue differences in adult and pediatric patients.

GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve diagnostic clarity across several clinical scenarios. - Central nervous system imaging: Improves lesion detection and delineation in brain and spinal cord studies. - Vascular imaging: Enhances visualization of arteries, veins and aneurysms. - Whole‑body and oncologic imaging: Improves detection of metastatic disease and tumor margins. - Cardiac MRI: Provides clearer definition of myocardial perfusion and scar tissue. - Pediatric MRI: Facilitates better contrast in children’s neuro‑vascular studies.

Adverse reactions to Omniscan are generally uncommon but can range from mild to severe.

Common Side Effects: - Nausea: Mild, transient feeling of stomach upset. - Headache: Temporary headache occurring shortly after injection. - Injection site discomfort: Minor pain or burning at the site of administration. - Warmth sensation: Brief feeling of warmth or flushing. - Dizziness: Light‑headedness that resolves quickly.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis (NSF): A rare fibrotic disorder in patients with severe renal impairment. - Severe allergic reaction: Anaphylaxis or anaphylactoid responses requiring immediate medical attention. - Cardiac arrest: Extremely rare but potentially life‑threatening event. - Pulmonary edema: Accumulation of fluid in the lungs, observed in isolated cases. - Acute kidney injury: Deterioration of renal function following exposure.

When using Omniscan, clinicians should assess patient history and monitor for specific risks. - Renal function assessment: Evaluate glomerular filtration rate before administration. - History of allergic reactions: Review prior contrast media reactions. - Pregnancy considerations: Use only if clearly needed, weighing fetal risk. - Pediatric dosing: Adjust volume based on weight and clinical protocol. - Concomitant nephrotoxic drugs: Avoid or monitor use of other renal‑impacting agents. - Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze or shake.

Omniscan may interact with other agents that affect renal function or hypersensitivity risk.

Major Interactions (Avoid): - Loop diuretics: May exacerbate renal impairment when combined with gadolinium agents. - High‑dose intravenous iron: Can increase the risk of free gadolinium release.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): May compound renal stress. - Metformin: Requires temporary discontinuation in patients with reduced kidney function. - ACE inhibitors/ARBs: May affect renal haemodynamics, necessitating close monitoring. - Radiopharmaceuticals: Concurrent use may alter imaging interpretation.